Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Announces Pivotal Phase III Data of Flibanserin in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder
Published in Women's Health Weekly, December 3rd, 2009
Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD). Flibanserin is an investigational compound being developed by Boehringer Ingelheim for the treatment of HSDD in pre-menopausal women. HSDD is a decrease or lack of sexual desire that causes distress for the patient, may put a strain on relationships with partners, and is not due to the effects of a substance, including medications, or another medical condition.
To view the Multimedia News Release, go to:...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- American Academy of Neurology
Good news on multiple sclerosis and pregnancy - Georgetown University Medical Center
For many, mammography every other year has benefits of annual screening, but less harm - University of Pennsylvania School of Medicine
Weight training boosts breast cancer survivors' body image and intimate relationship satisfaction - University of Rochester Medical Center
Pilot study relates phthalate exposure to less-masculine play by boys - Apoptosis
Research on apoptosis described by S. Aroui and colleagues - Apoptosis
Studies conducted at University of Louisiana on apoptosis recently published - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
